Background: As the American population is aging, the number of older people with inflammatory bowel disease is increasing. We used clinical data
s the American population is aging, the number of people with a new diagnosis of inflammatory bowel disease (IBD) at an older age and the number of people who age with IBD is increasing. Approximately 15% of cases are diagnosed after the age of 65. 1, 2 It is widely known that the U.S. population is aging. 3 Therefore, the number of people with a new diagnosis of IBD at older ages will increase, as will the number of younger patients with IBD become old. 2, 4, 5 IBD in the older population is not very well characterized. Important differences could exist among older adults who develop IBD at younger ages as compared to those with new-onset IBD at an older age. We require a thorough understanding of how the disease process differs in older adults to best balance comorbidities, polypharmacy, and use of resources in treating older patients with IBD. 6 Previous reports of IBD in older adults have often focused on those who are newly diagnosed at an older age; less is known about how IBD evolves with age as patients with IBD survive longer. 5, [7] [8] [9] [10] [11] There is also a need to understand how IBD differs between those who age with the disease and those who are newly diagnosed at an older age.
Treatment of IBD in older adults is also not well understood. The first practical treatment guidelines for IBD in the elderly were published in 1997. 12 Numerous studies note that corticosteroids are not optimal first-line agents for treatment of IBD in older adults. 7, 12, 13 However, recent studies reveal that corticosteroids are widely used for maintenance in elderly patients with IBD. [14] [15] [16] [17] Other studies recommend against using a combination of immunosuppressive agents in older individuals due to an increased risk of infectious and neoplastic complications. 7, 9, 15, [18] [19] [20] However, this greater risk of infectious or neoplastic complications in older patients with IBD has not been well established in the literature. 21 A more recent study suggests that older patients with IBD have a lower rate of short-term clinical response with the use of anti-tumor necrosis factor (TNF) therapy. 19 There is international variation in prescription patterns of older patients with IBD, 22 which reflects the need to have a better understanding of therapeutic options and medication side effects.
To better understand and examine the characteristics and course of IBD in older adults, we used baseline data from the Sinai-Helmsley Alliance for Research Excellence (SHARE), a prospective cohort to examine differences in various disease and treatment characteristics by age at IBD onset.
METHODS

Data Source
The Sinai-Helmsley Alliance for Research Excellence (SHARE) is a prospective observational cohort of patients with IBD. The data for this study are obtained from the baseline interview of subjects at study enrollment. The cohort was established with the goal of creating a database of clinical information as well as a repository of biological specimens for genetic, molecular, and microbiological research to better understand IBD and help develop new therapies. Patients were recruited from 7 academic centers around the United States: Mount Sinai Hospital, University of Chicago Medical Center, Massachusetts General Hospital, Cedars-Sinai Medical Center, Mayo Clinic, Rochester, University of North Carolina at Chapel Hill Hospital, and Washington University, Saint Louis, Medical Center. The institutional review boards of all institutions approved this study.
Patients who were younger than 18 years, unable to understand or provide informed consent and did not have a confirmed diagnosis of IBD in their medical records, were excluded. Consented patients provided demographic information, medical history, surgical history, including perianal procedures, family history, medication use, extraintestinal manifestations, and blood samples through an interview with a study coordinator. Disease characteristics, medication use, extraintestinal manifestations, and laboratory results were obtained from the medical record. A modified Harvey-Bradshaw Index (HBI) or Simple Clinical Colitis Activity Index (SCCAI) was completed during the study visit. Remission was defined as an HBI under 5 or an SCCAI of 2 or under. 23, 24 
Statistical Analysis
We assessed demographics, disease behavior, and medical history for enrolled patients at baseline when the cohort was initiated. We performed a cross-sectional analysis comparing these factors in strata of IBD subtype (Crohn's disease [CD] or ulcerative colitis [UC] ) and age at diagnosis. Patients diagnosed after age 60 were defined as "older-onset," patients diagnosed before age 60 but are currently older than 60 years were defined as "younger-onset," and the remainder of patients, those who were younger than age 60, were defined as "young patients."
We used univariate analyses, chi-square tests, t tests, and analyses of variance as appropriate to determine the associations between older-onset, younger-onset, and young patients with factors such as demographics, disease behavior, and treatments. We analyzed surgical and remission status stratified by medications and disease behavior. We used logistic regression models to evaluate and adjust for confounders for surgical status and remission. After fitting the initial model with all the potential confounders, we used a change-in-effect method to drop variables that did not confound the relationship. If the adjusted odds ratio differed by less than 10% when a covariate was removed from the model, that covariate was not considered to be a confounder. A P value of less than 0.05 was considered to be significant. Statistical testing was not performed when there were no a priori hypotheses. All analyses were performed with Stata 14.0 (College Station, TX). Older-onset patients are those who are diagnosed $60 years, younger-onset patients are those who are diagnosed ,60 years but are currently $60 years, and young patients are those who are ,60 years. Numbers are percents unless otherwise indicated.
RESULTS
Crohn's Disease
A total of 5929 patients with a diagnosis of CD or UC were enrolled across 7 centers in the United States between July 2012 and December 2015.
Among patients with CD, 91 had older-onset disease, 389 had younger-onset disease, and 3431 were young (Table 1) . Average disease duration was 12 years in the young, 28 years in the younger-onset, and 3 years in the older-onset patients. There were no significant differences in sex, race, or ethnicity.
CD behavior differed between young and younger-onset patients (Table 1) . Compared with the younger-onset group, young patients had more inflammatory disease (49% versus 43%), less stricturing disease (27% versus 36%), and more penetrating disease (24% versus 21%, P , 0.01). There were no significant differences in disease behavior between olderonset patients compared with younger-onset and young patients. There were no differences in the incidence of perianal disease between the 3 groups. Older-onset patients had more ileal-only (37%) or colonic-only (27%) disease and less ileocolonic disease (36%) compared with younger-onset and young patients (P , 0.01). Young patients had more upper gastrointestinal (GI) disease (6%) compared with younger-onset patients only (2%, P , 0.01).
The mean modified HBI differed between the 3 groups (Table 1) . Mean HBIs were 4.3 in the young, 4.2 in the youngeronset, and 2.9 in the older-onset patients with CD. When evaluated by HBI scores in remission, older-onset patients had 1.78 times the odds of being in remission compared with the young (95% confidence intervals [CIs], 1.05-3.02) after adjusting for disease behavior, location, and medications (Table 2 ). There were no significant differences in remission status by HBI between younger-onset and young patients.
Older-onset patients with CD had less GI surgery (35%) compared with young patients with CD (50%) who had less GI surgery than younger-onset patients (67%, P , 0.01) ( Table 1) . After adjusting for disease duration, the only significant difference was that younger-onset patients with CD had 0.68 times the odds of undergoing surgery compared with young patients with CD (95% CI, 0.52-0.9) ( Table 2) .
Because older-onset patients had a shorter duration of disease than the other groups of patients, we assessed whether CD was different between older-onset patients and young patients within 5 years of diagnosis (Table 3 ). There were no differences in disease behavior or location. There was also no difference in surgical status even after controlling for confounders. After adjusting for disease behavior, location, and medications, newly diagnosed older-onset patients with CD had 2.42 times the odds of being in remission by HBI compared with newly diagnosed young patients with CD (95% CI, 1.24-4.72). A stratified analysis of remission by medications and disease behaviors revealed that the only significant difference was that newly diagnosed olderonset patients with inflammatory disease were more likely to be in remission than newly diagnosed young patients with CD (P ¼ 0.03).
Significant differences existed in medication utilization (Table 4) . Young patients were receiving more anti-TNF and thiopurine drugs compared with younger-onset and older-onset patients (P , 0.01). Young patients were more often treated with combination anti-TNF and thiopurine therapy (17%) compared with younger-onset patients (5.4%, P , 0.01). Older-onset patients reported 9.3% use of combination anti-TNF and thiopurine therapy, which did not differ significantly from young and younger-onset patients. Young patients with CD reported less current oral mesalamine use (17%) compared with youngeronset (24%) and older-onset (27%) patients (P , 0.01). There was no significant difference in current corticosteroid use between the 3 groups of patients. Older-onset patients had less lifetime exposure to corticosteroids (71%) compared with younger-onset (85%) or young patients (83%, P , 0.01). In a subgroup comparison of young and older-onset patients with CD in the first 5 years of diagnosis, young newly diagnosed patients were more often currently treated with anti-TNF agents, thiopurines, and a combination of anti-TNF agents and thiopurines (Table 3) . There were no other significant differences in medication use patterns, including corticosteroid use.
Ulcerative Colitis
Among patients with UC, 98 had older-onset UC, 218 had younger-onset, and 1702 people were young (Table 5) . Average disease duration was 9 years in the young, 24 years in the younger-onset, and 4 years in the older-onset patients. There were no differences in sex, race, disease extent, and mean SCCAI among the 3 groups.
Younger-onset patients with UC reported more GI surgery (25%) compared with young patients (16%), who had more surgery than older-onset patients (5%, P , 0.01) ( Table 5 ). There were no meaningful differences in the proportion of surgeries that were colectomies. After adjusting for disease duration and remission by SCCAI, the only significant difference was that olderonset patients with UC were at 0.22 times the odds of having surgery compared with the younger-onset patients (95% CI, 0.06-0.83) ( Table 2) .
To assess whether UC was different between older-onset patients with UC within 5 years of diagnosis and young patients with UC within 5 years of diagnosis, we compared the 2 groups (Table 6 ). There were no significant differences in demographics, disease extent, or SCCAI scores. Similar to patients with CD, there was no difference in surgical status even after controlling for confounders. In contrast to patients with CD, there was no difference in odds of remission between newly diagnosed young and older-onset patients.
Young patients with UC reported more current anti-TNF agent use (26%) compared with younger-onset patients only (17%, P , 0.01) ( Table 4 ). Young patients also reported more current treatment with a combination anti-TNF agent and thiopurine (9%) compared with the younger-onset (2%) and older-onset (3%) patients (P , 0.01). Older-onset patients also reported more current treatment with an oral mesalamine agent (72%) compared with the younger-onset (52%) and young (49%) patients (P , 0.01). There was no difference in the use of systemic corticosteroids between the 3 groups.
In a subgroup analysis of young and older-onset patients with UC within 5 years of diagnosis, young newly diagnosed patients with UC reported more use of thiopurine therapy (31% versus 18%, P ¼ 0.02) and combination therapy anti-TNF and thiopurine therapy (12% versus 3%, P ¼ 0.04) ( Table 6 ). Newly diagnosed older-onset patients with UC reported more treatment with oral mesalamine agents (71% versus 50%, P , 0.01) and anti-integrin inhibitors (6% versus 2%, P ¼ 0.01). There were no differences in the surgery or remission by SCCAI between the 2 groups.
DISCUSSION
We present data from one of the largest cohorts of younger-onset and older-onset patients with IBD to date. Analyzing the data in 3 strata-younger than age 60 (young), diagnosed before the age of 60 years, but are currently older than 60 years (younger-onset), and diagnosed after the age of 60 years (older-onset)-can help draw distinctions between patients who develop IBD at an older age to those who develop IBD earlier in life and live beyond 60 years. Comparing older-onset patients with young patients within 5 years of diagnosis can help determine whether older-onset disease is truly different, as the literature currently suggests. When comparing older-onset patients with young patients within 5 years of diagnosis, there were no differences in disease behavior or location for CD and extent of disease for UC. The need for surgery can be a marker of severity in IBD. After controlling for disease duration, there was no difference in surgical rates between the 3 groups of patients with CD, which is consistent with data from a recently published Canadian population-based study. 25 As expected, patients with longer disease duration were more likely to have stricturing disease, which speaks to the validity of the sample. Together, this information suggests that CD in older-onset patients may not truly be a milder disease process. Among patients with UC, there was no difference in disease extent, mean SCCAI scores, remission status by SCCAI, or surgery, suggesting that older-onset UC may not be a milder disease process. This is contrary to the findings of a recent Canadian population-based study, which suggests that surgery may not simply be a marker of severe disease but can also indicate patient preference to avoid the complications of medical therapy. 25 However, as the older-onset population in this cohort may have more severe disease, as indicated by high use of anti-TNF agents compared with previously reported cohort and metaanalyses, 15, 17, 26 we would expect that differences in disease would be more apparent; the lack of a difference between the older-onset patients with IBD and young patients with IBD further strengthens the argument that the disease may not be different.
Two recent population-based studies of older-onset IBD reached conflicting conclusions regarding the course of disease in older adults. 5, 11 In common with these studies, we also report that patients diagnosed with CD at an older age have less ileocolonic disease. Unlike both these recent studies, we also present data from people who age with IBD. A recent meta-analysis of IBD phenotype and clinical outcomes in older-onset patients with IBD suggests that older-onset patients with IBD may have less complicated disease. However, this review does report similar or higher rates of surgery, supporting our findings that older-onset patients with IBD may have more aggressive or poorly treated disease. 26 It is possible that older adults may elect to be surgically Older Onset (n ¼ 98) TNF   a   23  17  26  35  32  45  Thiopurines   b   23  24  30  43  47  56  Methotrexate  3  2  3  8  8  8  5-ASA   c   72  54  49  90  91  93  Corticosteroids  14  14  16  80  85  86  Budesonide  3  3  4  14  17  17  Narcotics  6  8  6  29  33  36 Older-onset patients are those who are diagnosed $60 years, younger-onset patients are those who are diagnosed ,60 years but are currently $60 years, and young patients are those who are ,60 years. All numbers are percents. managed in light of data from Medicare and Medicaid beneficiaries suggesting improved survival for older adults with UC who undergo and elective colectomy compared with those who pursue medical management. 27 However, a more recent analysis of a national database concluded that older adults with IBD are at a substantially higher risk for postoperative mortality and morbidity, 28 in which case, aggressive medical management may be warranted to prevent surgery. Previous literature suggests that anti-TNF use is very low in older patients with IBD. 15 Our results support this as well. Young patients with CD were more likely to be treated with anti-TNF agents, thiopurines, and combination anti-TNF and thiopurine therapy compared with younger-onset and olderonset patients with CD. In patients with UC, young patients had more current and ever use of anti-TNF agents compared with the younger-onset patients. There was less anti-TNF use in the older-onset patients with UC compared with young patients. Decreased use of anti-TNF agents in older adults may be explained by the described risks of aggressive immunosuppression in older people. 9, 19 However, reports that note a higher rate of complications in older patients who are treated with immunosuppression also note that there is a paucity of high-quality data evaluating treatment-related outcomes in older patients with IBD. [7] [8] [9] 18, 21 A more recent study reported lower rates of noninfectious complications and a similar rate of infectious complications in elderly-onset patients with CD compared with young controls. 9 It is also possible that comorbidities and polypharmacy may limit the use of biological agents in older adults. 14, 29 Despite having similar disease behaviors, olderonset patients with CD have lower rates of anti-TNF use than young patients with CD within the first 5 years of diagnosis. Therefore, decreased use of aggressive immunosuppression in older adults is likely not a reflection of milder disease behavior, but of more conservative prescribing patterns. If, in fact, older-onset CD is not a milder disease process, older patients may benefit from more aggressive disease management strategies that might prevent disease-related complications and surgery. This is especially the case for older-onset CD patients with stricturing and penetrating disease who may be undertreated. Although previous literature suggests that the older-onset patients have more systemic corticosteroid use, 14, 16, 17 our data do not support this. It is notable that older-onset patients with CD had less lifetime exposure to systemic corticosteroids compared with the young and younger-onset patients with CD. There were also no differences in corticosteroid use among patients with UC. Given the increasing recognition of the dangers of long-term corticosteroid use in older adults, 8 it is possible that prescribing patterns are changing.
There are numerous strengths to this large cross-sectional study of disease and treatment characteristics in older patients compared younger patients with IBD. Data are validated from the medical record, with accurate depiction of disease phenotype. The sample also draws from geographically diverse locations throughout the United States. This study also has some limitations. All the patients were treated at tertiary care centers across the United States, although we have previously reported variability in medication approaches in these centers. 30 Older literature reported that 15% of new cases of IBD are diagnosed over the age of 60 1,2 ; however, our study enrolled a lower percentage of older-onset subjects. These factors may limit the external generalizability of our study. In addition, we do not have data on objective inflammatory data such as biomarkers or endoscopic scales of disease activity. Furthermore, we do not have information on all comorbidities. As this study only includes cross-sectional data, we do not have longitudinal follow-up data; the goal of the SHARE cohort is to accrue this information.
We did not find evidence of a different disease process in older-onset patients with CD, especially those with stricturing and penetrating disease. Disease behavior and the need for surgery in newly diagnosed older-onset patients with CD were similar to those of newly diagnosed young patients with CD. Newly diagnosed older-onset CD patients with inflammatory disease had a higher odds of being in remission; however, there was no difference in the need for surgery. Disease characteristics, remission status, and the need for surgery were similar in UC populations. We also found that older patients with CD and UC were less likely to be treated with immunosuppressive medications. Older patients are believed to be at increased risk for complications from the immunosuppressive medications. However, as they may not ultimately have different disease processes, this treatment approach may be risking poor disease control and unintended consequences of suboptimally controlled disease over time.
